ibandronate, Boniva (cont.)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
Low calcium levels may occur if calcium and vitamin D intake is not adequate. Severe irritation of the esophagus (for example, esophagitis, esophageal ulcers, esophageal erosions) can occur. This occurs more often when patients do not drink enough water with ibandronate, wait less than 60 minutes before lying down after taking ibandronate, or continue to take ibandronate after developing symptoms of esophageal irritation. Ibandronate should not be used by individuals with abnormalities of the esophagus.
Patients may experience jaw problems (osteonecrosis of the jaw) associated with delayed healing and infection after tooth extraction.
GENERIC AVAILABLE: Yes
PREPARATIONS: Tablets: 150 mg; Intravenous injection, 3 mg/3 ml
STORAGE: Ibandronate tablets should be stored at room temperature, 15 C - 30 C (59 F - 86 F).
DOSING: The dose of ibandronate is 150 mg orally once monthly. The tablet should be taken on the same day of each month. Tablets should be taken at least 60 minutes before the first food or drink of the day (other than plain water) or before other oral medication, because of concern that that food or medication will interfere with the absorption of ibandronate. Absorption of ibandronate from the intestine is poor, and any potential further decrease in absorption by food or medications needs to be avoided.
Ibandronate tablets also should be swallowed whole with six to eight ounces of plain water while in an upright position, in order to be certain that the tablets enter the stomach. If the tablets stick in the esophagus they can irritate the esophagus. For the same reason, patients should not lie down for 60 minutes after taking ibandronate since tablets are more likely to stick in the esophagus when lying down.
Tablets should not be chewed or sucked in order to avoid irritation of the mouth and throat.
The dose of ibandronate administered intravenously is 3 mg administered over 15-30 seconds every three months.
DRUG INTERACTIONS: Calcium supplements, antacids, and other products that contain aluminum, magnesium, or iron may reduce absorption of ibandronate. Ibandronate should be administered at least 60 minutes before administration of any oral medication, including medications containing iron, aluminum, magnesium, or calcium.
Medically Reviewed by a Doctor on 2/25/2015
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index
- Allergic Skin Disorders
- Bacterial Skin Diseases
- Bites and Infestations
- Diseases of Pigment
- Fungal Skin Diseases
- Medical Anatomy and Illustrations
- Noncancerous, Precancerous & Cancerous Tumors
- Oral Health Conditions
- Papules, Scales, Plaques and Eruptions
- Scalp, Hair and Nails
- Sexually Transmitted Diseases (STDs)
- Vascular, Lymphatic and Systemic Conditions
- Viral Skin Diseases
- Additional Skin Conditions